VAERS Reports UJ966AA

VAERS 2722922

SANOFI PASTEUR · YELLOW FEVER (YF-VAX) · Charge uj966aa

schwer

Staat: CA
Alter: 16,0
Geschlecht: F
Eingang: 11.12.2023
Impfdatum: 06.12.2023
Beginn: 06.12.2023
Tage bis Beginn: 0,0
Dosis: 1
Route/Site: SC / LA

Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: ja Erholt: ja

Blood glucose normal Dizziness Headache Laboratory test normal Paraesthesia Syncope

Symptomtext

Pt started having a headache 10 minutes after receiving vaccine. She got up to tell her mom and fainted in her mom's arms. Pt was then positioned in a chair with legs elevated and came through shortly after. Her fingers were tingly and she felt extremely dizzy. paramedics came and took her vitals which were normal, blood sugar was alsonormal. Pt was taken to ER for monitoring. Every tests came back normal.

Weitere VAERSDATA-Felder

Praegender Schweregrund: Syncope
Hospital-Tage: -
Labordaten: All labs normal in ER according to mom
Aktuelle Erkrankungen: none
Vorgeschichte: none
Andere Medikamente: none
Allergien: none
Vorherige Impfungen: -

VAERS 2726257

SANOFI PASTEUR · YELLOW FEVER (YF-VAX) · Charge UJ966AA

mild

Staat: MN
Alter: 31,0
Geschlecht: F
Eingang: 21.12.2023
Impfdatum: 18.12.2023
Beginn: 18.12.2023
Tage bis Beginn: 0,0
Dosis: N/A
Route/Site: SC / RA

Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: ja Erholt: ja

Chest discomfort Dry throat Injection site urticaria Pruritus

Symptomtext

Approximately 10-15 minutes following above vaccinations (at 9:55 am), patient began to have hives at the injection site where the Yellow Fever vaccine was administered. There were approximately 3 hives within 1-2 inches from injection site. She then began to feel some dry sensation in her throat and was transferred to Urgent Care at 10:00am (located in same building at medical facility). Began to report itching on her chin and then several minutes later a slight heaviness in the chest. Patient was transferred to Urgent Care, was treated with Cetirizine Hydrochloride 10 mg at 10:22am, then Epinephrin injection at 10:59 am. Additionally was given 1 Liter of Normal Saline by IV which started at 11:05 am. She was monitored for 1.5 hours and was discharged home with full resolution of symptoms.

Weitere VAERSDATA-Felder

Praegender Schweregrund: Injection site urticaria
Hospital-Tage: -
Labordaten: n/a
Aktuelle Erkrankungen: None known
Vorgeschichte: Anxiety disorder Dysmenorrhea Endometriosis Hyperlipidemia Psoriasis
Andere Medikamente: bergamot supplement [Free Text]; 2 CAPSULES DAILY L-thionine [Free Text]; 1 CAPSULE HS Magnesium Sulfate; 2 CAPSULES HS Prenatal; PNV, 3 TABS DAILY - PT USES THIS AS MVI Probiotic Product CAPS; 1 CAPSULE DAILY Vitamin D3; DROPS DAILY, UNKNO
Allergien: VERSED
Vorherige Impfungen: -

VAERS 2727502

SANOFI PASTEUR · YELLOW FEVER (YF-VAX) · Charge UJ966AA

gering

Staat: AZ
Alter: -
Geschlecht: M
Eingang: 27.12.2023
Impfdatum: -
Beginn: -
Tage bis Beginn: -
Dosis: UNK
Route/Site: OT / -

Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein

Incorrect route of product administration No adverse event

Symptomtext

accidentally administered YF-VAX to patient intramuscularly instead of subcutaneously with no reported adverse event; Initial information received from Regulatory Authority on 19-Dec-2023 regarding an unsolicited valid non-serious case received from a Pharmacist. This case is linked to case 2023SA396932 (RA). This case involves an unknown age male patient who accidentally administered YELLOW FEVER VACCINE - US [YF-VAX] to patient intramuscularly instead of subcutaneously with no reported adverse event. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On an unknown date, the patient received a dose of suspect yellow fever vaccine - RA Solution for injection (lot- UJ966AA and expiration date- 05-Jan -2025) via intramuscular route in unknown administration site (dose, strength: not provided) for Immunisation (incorrect route of product administration) (latency- same day). This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.

Weitere VAERSDATA-Felder

Praegender Schweregrund: Incorrect route of product administration
Hospital-Tage: -
Labordaten: -
Aktuelle Erkrankungen: -
Vorgeschichte: -
Andere Medikamente: -
Allergien: -
Vorherige Impfungen: -

VAERS 2727501

SANOFI PASTEUR · YELLOW FEVER (YF-VAX) · Charge UJ966AA

gering

Staat: AZ
Alter: -
Geschlecht: F
Eingang: 27.12.2023
Impfdatum: -
Beginn: -
Tage bis Beginn: -
Dosis: UNK
Route/Site: OT / -

Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein

Incorrect route of product administration No adverse event

Symptomtext

accidentally administered YF-VAX intramuscularly instead of subcutaneously with no reported adverse event; Initial information received on 19-Dec-2023 regarding an unsolicited valid non-serious case received from a Pharmacist. This case involves an unknown age female patient who accidentally administered YELLOW FEVER VACCINE [YF-VAX] intramuscularly instead of subcutaneously with no reported adverse event. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On an unknown date, the patient received a dose of suspect yellow fever vaccine - Solution for injection (lot- UJ966AA and UJ819AA, expiration date- 01-May-2025 and 18-Apr-2024) via intramuscular route in unknown administration site (dose, strength: not provided) for Immunisation (incorrect route of product administration) (latency- same day). This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.

Weitere VAERSDATA-Felder

Praegender Schweregrund: Incorrect route of product administration
Hospital-Tage: -
Labordaten: -
Aktuelle Erkrankungen: -
Vorgeschichte: -
Andere Medikamente: -
Allergien: -
Vorherige Impfungen: -